[2010 Chinese guidelines for the management of hypertension] - PubMed (original) (raw)
Practice Guideline
. 2011 Jul;39(7):579-615.
[Article in Chinese]
Affiliations
- PMID: 22088239
Practice Guideline
[2010 Chinese guidelines for the management of hypertension]
[Article in Chinese]
Li-Sheng Liu et al. Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Jul.
Abstract
The 2010 Chinese guidelines for the management of hypertension is an update of the previous versions in 2005 and 1999. A guideline committee of nearly 100 members appointed by the Chinese Hypertension League (CHL) and the National Centre for Cardiovascular Disease (NCCD), in collaboration with the Chinese societies of cardiology, nephrology, neurology, gynecology and endocrinology, convened on several occasions and discussed the guidelines, drafted by a core writing group. The prevalence of hypertension has been increasing in China for decades, and reached 18.8% in the year 2002. The rates of awareness, treatment and control for hypertension patients remain low compared to high income countries, in spite of substantial improvements since 1991. In some communities, the control rate of hypertension increased up to 60%. The mortality rate of stroke, which is the major complication of hypertension in the Chinese population, gradually decreased during the period, more so in urban areas than in rural areas for the middle-aged and elderly populations; in the younger age groups, however, it increased. As hypertension is a "cardiovascular syndrome", the management strategy should be based on the overall risk of cardiovascular disease estimated with all related risk factors, target organ damage and co-morbidity of patients. The target blood pressure is set at SBP/DBP < 140/90 mm Hg (1 mm Hg = 0. 133 kPa) in uncomplicated hypertension; < 150/90 mm Hg for the elderly (> or = 65 years) or, if tolerable, < 140/90 mm Hg; and < 130/80 mm Hg for those with diabetes, coronary heart disease or renal disease. For these high risk patients, the management should be individualised. In general, lifestyle modification, such as sodium restriction, smoking cessation, moderation of body weight and alcohol consumption, and increasing dietary potassium intake and physical activity, should be implemented for prevention and control of hypertension. Five classes of antihypertensive drugs, including calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin type II receptor blockers, diuretics and beta-blockers, as well as single pill combinations of these agents, can be used for initial and maintenance of antihypertensive treatment. Several populations require special attention in the prevention and control of hypertension, such as children and adolescents, the elderly, pregnant women, and patients with various cardiovascular complications. Since health-care policies and resources vary substantially from one place to another, two levels of recommendations of management are proposed: a sophisticated and a basic, allowing doctors-in-charge to manage their patients in a more feasible way.
Similar articles
- Lifestyle modifications to prevent and control hypertension. 1. Methods and an overview of the Canadian recommendations. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada.
Campbell NR, Burgess E, Choi BC, Taylor G, Wilson E, Cléroux J, Fodor JG, Leiter LA, Spence D. Campbell NR, et al. CMAJ. 1999 May 4;160(9 Suppl):S1-6. CMAJ. 1999. PMID: 10333847 Free PMC article. - The future of antihypertensive treatment.
Israili ZH, Hernández-Hernández R, Valasco M. Israili ZH, et al. Am J Ther. 2007 Mar-Apr;14(2):121-34. doi: 10.1097/01.pap.0000249915.12185.58. Am J Ther. 2007. PMID: 17414579 Review. - The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
Khan NA, McAlister FA, Campbell NR, Feldman RD, Rabkin S, Mahon J, Lewanczuk R, Zarnke KB, Hemmelgarn B, Lebel M, Levine M, Herbert C; Canadian Hypertension Education Program. Khan NA, et al. Can J Cardiol. 2004 Jan;20(1):41-54. Can J Cardiol. 2004. PMID: 14968142 - The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW, Leiter LA, Lebel M, Herbert C, Schiffrin EL, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, DeChamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Campbell NR, Arnold M, Moe G, Hill MD, Jones C, Larochelle P, Ogilvie RI, Tobe S, Houlden R, Burgess E, Feldman RD; Canadian Hypertension Education Program. Khan NA, et al. Can J Cardiol. 2005 Jun;21(8):657-72. Can J Cardiol. 2005. PMID: 16003449 - New treatment guidelines for a patient with diabetes and hypertension.
Mogensen CE. Mogensen CE. J Hypertens Suppl. 2003 Mar;21(1):S25-30. J Hypertens Suppl. 2003. PMID: 12769164 Review.
Cited by
- Prevalence of Poor Sleep Quality in Patients With Hypertension in China: A Meta-analysis of Comparative Studies and Epidemiological Surveys.
Li L, Li L, Chai JX, Xiao L, Ng CH, Ungvari GS, Xiang YT. Li L, et al. Front Psychiatry. 2020 Jun 30;11:591. doi: 10.3389/fpsyt.2020.00591. eCollection 2020. Front Psychiatry. 2020. PMID: 32695027 Free PMC article. - Therapeutic effects of intravenous urapidil in elderly patients with hypertension and acute decompensated heart failure: A pilot clinical trial.
Yang W, Zhou YJ, Fu Y, Qin J, Tan S, Chen XM, Guo JC, Wang DZ, Zhan H, Guan W, Xu YW, He JY, Li J, Hua QI. Yang W, et al. Exp Ther Med. 2016 Jul;12(1):115-122. doi: 10.3892/etm.2016.3302. Epub 2016 Apr 27. Exp Ther Med. 2016. PMID: 27347026 Free PMC article. - The impact of increasing expenditure on National Essential Public Health Services on the medical costs of hypertension in China: A difference-in-difference analysis.
Xue L, Sui M, He Y, Li H, Ying X. Xue L, et al. PLoS One. 2022 Nov 28;17(11):e0278026. doi: 10.1371/journal.pone.0278026. eCollection 2022. PLoS One. 2022. PMID: 36441726 Free PMC article. - Effectiveness of integrated care for older adults with depression and hypertension in rural China: A cluster randomized controlled trial.
Chen S, Conwell Y, Xue J, Li L, Zhao T, Tang W, Bogner H, Dong H. Chen S, et al. PLoS Med. 2022 Oct 24;19(10):e1004019. doi: 10.1371/journal.pmed.1004019. eCollection 2022 Oct. PLoS Med. 2022. PMID: 36279299 Free PMC article. Clinical Trial. - Consensus of Chinese Specialists on Diagnosis and Treatment of Resistant Hypertension.
Sun NL, Huo Y, Wang JG, Li NF, Tao J, Li Y, Yan XW, Jiang XJ, Li XW. Sun NL, et al. Chin Med J (Engl). 2015 Aug 5;128(15):2102-8. doi: 10.4103/0366-6999.161395. Chin Med J (Engl). 2015. PMID: 26228226 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials